TransMedics Group, Inc. (TMDX)

TMDX Cash Flow Statement

Operating, investing, and financing cash flow analysis

TMDX Quarterly Cash Flow Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024	06/30/2024
Cash from Operations (CFO)	220.228M	24.533M	34.513M	69.573M	91.609M	-2.855M	19.663M	6.857M	25.718M
Net Income	171.924M	7.315M	105.383M	24.319M	34.907M	25.682M	6.857M	4.216M	12.194M
Depreciation & Amortization	32.912M	11.864M	7.468M	6.849M	6.731M	6.137M	5.680M	5.177M	4.599M
Stock-Based Compensation	37.855M	9.952M	9.395M	9.136M	9.372M	8.958M	10.767M	7.944M	7.643M
Change in Accounts Receivable	360.562M	90.727M	84.282M	80.702M	104.851M	142.026M	97.722M	90.128M	81.158M
Change in Inventory	—	—	—	—	—	—	—	—	—
Change in Accounts Payable	—	—	—	—	—	—	—	—	—
Change in Working Capital	51.821M	-11.354M	-4.941M	27.931M	40.185M	-44.400M	-5.832M	-11.249M	177K
Cash from Investing	—	—	—	—	—	—	—	—	—
Capital Expenditures (CapEx)	-68.870M	-36.657M	-15.514M	-7.624M	-9.075M	-27.038M	-13.606M	-48.203M	-23.763M
Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	441K	0.00
Cash from Financing	—	—	—	—	—	—	—	—	—
Debt Repayment	—	—	—	—	—	—	—	—	—
Stock Repurchased (Buybacks)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Free Cash Flow (FCF)	151.358M	-12.124M	18.999M	61.949M	82.534M	-29.893M	6.057M	-41.346M	1.955M
Net Change in Cash	169.534M	-8.689M	22.192M	65.599M	90.432M	-26.507M	6.556M	-32.657M	12.534M

TMDX Annual Cash Flow Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Cash from Operations (CFO)	192.840M	48.803M	-13.028M	-45.817M	-28.864M	-30.265M	-32.286M	-25.984M
Net Income	190.291M	35.464M	-25.028M	-36.231M	-44.215M	-28.748M	-33.547M	-23.756M
Depreciation & Amortization	27.185M	19.758M	8.177M	3.478M	1.817M	1.577M	1.222M	769K
Stock-Based Compensation	36.861M	33.224M	19.791M	10.321M	6.878M	2.414M	854K	144K
Change in Accounts Receivable	84.282M	97.722M	63.576M	27.611M	5.934M	6.864M	6.559M	3.438M
Change in Inventory	—	—	—	—	—	—	—	—
Change in Accounts Payable	—	—	—	—	—	—	—	—
Change in Working Capital	17.251M	-45.000M	-44.347M	-26.759M	3.003M	-5.588M	-1.626M	-4.327M
Cash from Investing	—	—	—	—	—	—	—	—
Capital Expenditures (CapEx)	-59.251M	-129.744M	-179.059M	-11.907M	-3.519M	-455K	-165K	-418K
Acquisitions	0.00	441K	-14.894M	107K	0.00	41.143M	60.336M	0.00
Cash from Financing	—	—	—	—	—	—	—	—
Debt Repayment	—	—	—	—	—	—	—	—
Stock Repurchased (Buybacks)	-138K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Free Cash Flow (FCF)	133.589M	-80.941M	-192.087M	-57.724M	-32.383M	-30.720M	-32.451M	-26.402M
Net Change in Cash	151.716M	-58.162M	193.630M	175.602M	999K	4.489M	-149K	8.305M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Andover, MA

728 employees

www.transmedics.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Waleed H. Hassanein

View full financials